Skip to nav Skip to content

Clinical Trial Search

376 Clinical Trials Found

Clinical Trial 22706

A Phase 1b/2 Open-Label Study of Disitamab Vedotin Monotherapy or in Combination with Other Anticancer Therapies in Solid Tumors
Disease Site: Breast
PI: Costa, Ricardo

Clinical Trial 21923

A Phase 1b/2 Multicenter, Open-label Study to Evaluate the Safety and Efficacy of TTI-101 as Monotherapy and in Combination in Participants with Locally Advanced or Metastatic, and Unresectable Hepatocellular Carcinoma
Disease Site: Liver
PI: Kim, Richard

Clinical Trial 23367

Disease Site: Breast
PI: Han, Heather

Clinical Trial 23341

A Randomized, Controlled, Multicenter, Phase 3 Clinical Study Comparing Vusolimoqene Oderparepvec in Combination with Nivolumab Versus Treatment of Physician's Choice in Patients with Advanced Melanoma that Has Progressed on an Anti-PD-1 and an Anti-CTLA-4 Containing Treatment Regimen
Disease Site: Melanoma, skin
PI: Khushalani, Nikhil

Clinical Trial 22263

A Phase 1b Study of Oral AS-1763 in Patients with Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or B-cell Non-Hodgkin Lymphoma
Disease Site: Lymphoid Leukemia, Non-Hodgkin's Lymphoma, Soft Tissue
PI: Pinilla-Ibarz, Javier

Clinical Trial 21415

Disease Site: Other Hematopoietic
PI: Kuykendall, Andrew

Clinical Trial 21951

A Randomized, Open-Label, Phase 3 Study to Evaluate Zimberelimab and Domvanalimab in Combination with Chemotherapy Versus Pembrolizumab with Chemotherapy for the First-Line Treatment of Patients With Metastatic Non Small Cell Lung Cancer With No Epidermal Growth Factor Receptor or Anaplastic Lymphoma Kinase Genomic Tumor Aberrations (STAR-121)
Disease Site: Lung
PI: Gray, Jhanelle

Clinical Trial 22695

ADI-PEG 20 (Pegargiminase) or Placebo (PBO) plus Gemcitabine and Docetaxel in Previously Treated Subjects with Leiomyosarcoma (ARGSARC): A Randomized, Double-Blind, Multi-Center Phase 3 Trial
Disease Site: Soft Tissue
PI: Druta, Mihaela

Clinical Trial 20733

A Phase III Trial to Evaluate the Efficacy of the Addition of Inotuzomab Ozogamicin (a conjugated anti-CD22 monoclonal antibody) to Frontline Therapy in Young Adults (ages 18-39 years) with Newly Diagnosed Precusor B-cell ALL
Disease Site: Myeloid and Monocytic Leukemia
PI: Vargas Madueno, Fernando

Clinical Trial 23785

Disease Site: Other
PI: Giuliano, Anna

Clinical Trial 23199

SR2204: A Randomized Phase III Trial of a Perioperative Physical Activity Intervention in Older Adults with Lung Cancer and their Family Caregivers
Disease Site: Lung
PI: Toloza, Eric

Clinical Trial 23230

Support through remote observation and nutrition guidance program for individuals with gastroesophageal cancer (STRONG-GEC)
Disease Site: Esophagus, Stomach
PI: Alishahi Tabriz, Amir